A cetylsalicylic acid (ASA) at doses of 75 mg/day to 325 mg/day (low-dose ASA [LDA]) is recommended for secondary prevention of cardiovascular events (1) and is also commonly used for primary prevention in patients with a markedly increased risk of cardiovascular events. LDA use has been shown to decrease the incidence of cardiovascular events in patients at high cardiovascular risk (2); however, its use is associated with an increased risk of upper gastrointestinal bleeding (UGIB) (3-5). Peptic ulcer bleeding (PUB) accounts for most of this increased risk (6).
addition, some studies limited inclusion to a single indication for ASA such as primary cardiovascular prevention (10) or secondary prevention (15) . The majority of reviews only included randomized controlled trials (RCTs) (8, (11) (12) (13) (14) (15) 18, 20) . However, many of the RCTs included in such reviews excluded patients at high risk for UGIB and, thus, may have underestimated the risk of bleeding associated with LDA use in real-world practice. One systematic review by García Rodríguez et al (9) included observational epidemiological studies published from 1990 to 2001, but no RCTs. Another review (16) included only casecontrol studies conducted before 1989.
The aim of the present study was to perform a meta-analysis of prospective RCTs that compared LDA therapy with placebo in different populations, regardless of indication, duration of follow-up or duration of use, as well as observational studies that evaluated the strength of the association between LDA use and UGIB risk specifically. In addition, the absolute increase in the risk of UGIB with LDA use compared with placebo was determined from RCTs.
MEtHodS

Study selection
The PubMed and Embase databases were searched (entries from 1989 to 2009) for RCTs reporting UGIB (including hematemesis and/or melena) or PUB involving individuals receiving LDA or placebo; and observational studies of LDA use in cases involving UGIB or PUB, or controls. The references from previous meta-analyses and reviews were also reviewed. Searches were limited to studies published in English, French, German, Spanish, Italian or Japanese. Search results were combined and duplicates were removed. Access (Microsoft Corporation, USA) was used to screen the search results in a structured manner. Initially, study titles were screened for relevance and identified for further screening using the abstract/full text. Studies were excluded if any of the following criteria applied: all studied ASA doses were >325 mg/day; ASA doses were not reported; all patients were undergoing gastroprotective therapy or receiving Helicobacter pylori eradication therapy; patients were taking nonsteroidal anti-inflammatory drugs (NSAIDs); or the absence of an appropriate control group(s). Studies were also excluded if UGIB or PUB rates were not reported separately from rates of lower gastrointestinal bleeding, rates of upper gastrointestinal complications were reported as a whole rather than UGIB specifically, or data were reported only for uncomplicated peptic ulcer disease. Study selection was performed independently by two authors and decisions regarding study inclusion were reached by consensus.
data extraction
Data regarding study populations, treatments and end points were independently extracted from each identified study by two authors and any discrepancies were resolved by consensus. For each treatment arm in the RCTs, the number of trial participants, the follow-up period and the number of patients who developed the primary end point of PUB or UGIB were recorded. Two of the RCT publications (21, 22) reported on melena and hematemesis separately. Only the hematemesis data from these two studies were included to minimize outcome misclassification and to avoid the possibility of double-counting UGIB events. In a sensitivity analysis, the melena data were included instead.
For the observational studies, the matching criteria, covariates in the model and adjusted OR with 95% CI were recorded. For all studies, the mean age at baseline and the percentage of male participants were assessed. For some of the studies (6, (22) (23) (24) , this involved referring to other published articles investigating the same study populations (25) (26) (27) (28) . For studies in which age was presented in categories, patient age was inferred to be the midpoint in the range. For example, for patients between 60 and 69 years of age, a mean age of 64.5 years was inferred.
data analysis
The rate of UGIB (per 1000 individuals per year) was calculated for each included RCT. The treatment-years weighted mean number of extra UGIB cases associated with LDA use (per 1000 individuals per year) was also calculated. The number needed to harm (NNH) -based on the inverse of the risk difference in patients using LDA compared with patients receiving placebo -was calculated for RCTs. For observational studies, the NNH was calculated (29) using the pooled OR provided by the meta-analyses of the observational studies, given a UGIB event rate of 59 per 100,000 person-years in subjects not exposed to ASA (derived from the cohort study by Sørensen et al [30] ). The NNH represents the number of patients needed to be exposed to LDA to cause UGIB in one patient.
The meta-analyses were based on the OR, which can be interpreted as an estimate of the relative risk (RR). The OR is defined as the odds of LDA exposure among patients with UGIB divided by the odds of exposure to LDA among those without UGIB. For the observational studies, the adjusted ORs or RRs, as reported in the original article, were pooled if possible; in one of the 11 studies (31), raw outcome data were used to calculate unadjusted ORs (which may be susceptible to confounding). None of the RCTs reported an RR; therefore, the crude OR and the corresponding 95% CI was calculated for UGIB comparing ASA therapy with placebo for each individual RCT (it was hypothesized that confounding was less of an issue in RCTs than in observational studies). To include the study by Silagy et al (32) , which had four confirmed UGIB cases in the ASA group but no cases in the placebo group, 0.1 events were added to both groups, resulting in 4.1 cases in the ASA group and 0.1 case in the placebo group. This avoided an infinite OR due to null events in the placebo group. In a sensitivity analysis, 0.5 events were added to both arms.
Given the potential diversity of study designs, stratified analyses according to the two groups were performed: RCTs and observational studies. Within the observational studies, a subgroup analysis of five studies was performed investigating ASA doses ≤100 mg and four studies investigating ASA doses 300 mg to 325 mg.
To estimate an overall pooled OR, a fixed-effects model was used for the RCTs (inverse variance model) using Mix version 1.7 (BiostatXL, USA) (33) . To be as conservative as possible, a random-effects model was also applied. For the observational studies, a random-effects model was used because statistical heterogeneity existed across the studies. Publication bias was examined using funnel plot asymmetry and quantified using the Egger regression test (34) . All statistical tests were two sided and P<0.05 was considered to be statistically significant.
Statistical heterogeneity
Statistical heterogeneity among the studies was tested using Cochran's Q statistic. For this test, a two-sided P≤0.10 was considered to indicate heterogeneity. To measure the degree of heterogeneity, an I 2 value was calculated, with I 2 values <30% representing a low level, 30% to 75% representing a moderate level and >75% representing a high level of heterogeneity.
rESuLtS
Search results
The PubMed and Embase database searches resulted in the identification of 2011 unique studies. The titles of these studies were screened for relevance and 709 studies were identified for further screening using the abstract/full text. A total of 688 studies were subsequently excluded for the reasons listed in Figure 1 , leaving a total of 21 studies (six RCTs and 15 observational studies) eligible for inclusion. The references from previous meta-analyses and reviews were also examined (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) and one additional eligible RCT was identified (22) . Thus, a total of 22 studies (seven RCTs and 15 observational studies) were eligible for inclusion (Figure 1 ). Of the 15 observational studies, 14 were case-control studies and one was a cohort study.
Of the 22 studies meeting all of the inclusion criteria, three (35-37) were suspected of reporting results from the same study populations as those included in more recently published articles (38, 39) , and one study (40) presented additional analyses from a sample that overlapped with a previous study (39) . Thus, the final number of studies included in the analyses was 18: seven RCTs (6,21,22,32,41-43) and 11 observational studies (23, 24, 30, 31, 38, 39, (44) (45) (46) (47) (48) .
Study characteristics
The main characteristics of the 18 studies included in the metaanalysis are summarized in (range 53.8 to 79.0 years) and 70.0% were male (range 21.0% to 100%). Mean follow-up periods ranged from 35 days to seven years. None of the RCTs tested more than one dose level of ASA; therefore, it was not possible to assess any potential dose-response relationship. observational studies: Eleven observational studies were identified, of which 10 were case-control studies and one was a cohort study. Five of the 10 case-control studies analyzed LDA use in patients presenting with UGIB (rather than PUB specifically) and controls with no UGIB (24, 38, 39, 44, 47) ; the other five examined LDA use in patients presenting with PUB and controls with no PUB (Table 2) (23, 31, 45, 46, 48) . A total of 41,335 patients were observed in the case-control studies, of whom 10,816 were UGIB cases and 30,519 were controls. In the The control groups used in the 10 case-control studies varied. Three studies used a control group comprising hospital patients (24, 45, 46) , three studies included a control group obtained from primary care or the general population (39, 44, 47) , and three studies included a combination of hospital patients and community-based controls (23, 31, 38) . One study used a control group of patients with endoscopically confirmed nonulcer dyspepsia (48) .
Four of the case-control studies examined the risks of PUB or UGIB associated with specific doses of ASA (23, 31, 44, 46) , while the other six grouped ASA doses into one or more dose ranges (24, 38, 39, 45, 47, 48) . The cohort study reported the standard incidence ratios (SIRs) of UGIB for doses of 100 mg/day and 150 mg/day, but it was unclear whether these findings were from a group of patients who were also being treated with other NSAIDs (30) .
Association between LdA use and uGiB rCts: During follow-up, 1.3% (288 of 22,901) of participants assigned to the ASA group developed UGIB. During the same period, 0.8% (194 of 22,923) of participants assigned to the placebo group developed UGIB.
All of the RCT publications reported increased rates of UGIB or PUB in individuals receiving LDA compared with those receiving placebo, of which two were statistically significant (6, 42) and five (21, 22, 32, 41, 43) were not. Across the various studies, UGIB rates were in the range of 0.6 to 328.1 per 1000 patients per year in the LDA group, and 0 to 231.3 per 1000 patients per year in the placebo group. Based on this analysis, the number of extra UGIB cases associated with LDA use ranged from 0.2 to 96.8 per 1000 patients per year. The personyears weighted average number of extra UGIB cases associated with LDA use was 1.2 per 1000 patients per year (95% CI 0.7 to 1.8). The NNH was 816 (95% CI 560 to 1500), meaning that if 816 individuals received LDA, one would have developed UGIB as a result of treatment.
After pooling the results, the OR of UGIB associated with LDA use was 1.5 (95% CI 1.2 to 1.8; P<0.0001) (Figure 2 ). There was no heterogeneity (I ² =0%) and, because this was not significant (P=0.50), a fixed-effects model was applied. The result of the Egger regression test for publication bias was not significant (intercept 0.8 [95% CI -0.3 to 1.9]; P=0.12) and no funnel plot asymmetry was observed ( Figure 3A) , indicating no evidence of publication bias. The pooled estimate was mostly driven by the Pulmonary Embolism Prevention trial (42) , with a relative weight of 75.6%.
As mentioned previously, two of the RCTs (21, 22) reported on hematemesis and melena separately. When the melena data of these studies were included instead of the hematemesis data, the association remained the same as in the primary analysis (OR 1.5 [95% CI 1.3 to 1.7]; P<0.0001; P for heterogeneity = 0.57, also using a fixed-effects model). In addition, a sensitivity analysis was performed by adding 0.5 events instead of 0.1 events to the placebo and LDA arms of the study by Silagy et al (32) , which did not influence the result. observational studies: All 11 observational studies reported a significant increase in the rate of PUB or UGIB in individuals treated with LDA compared with those who were not treated with LDA (Figure 4) .
The pooled OR of the meta-analysis of the observational studies examining the risk of UGIB associated with ASA use was 3.1 (95% CI 2.5 to 3.7; P<0.0001) (Figure 4 ). There was a high degree of heterogeneity (I²=78%); thus, a random-effects model was applied. The result of the Egger regression test for publication bias was not significant (intercept 1.6 [95% CI -1.1 to 4.2]; P=0.21) and no funnel plot asymmetry was apparent ( Figure 3B ), indicating no evidence of publication bias. As mentioned in the Methods section, in the study by Uppalapati et al (31) , raw outcome data were used to calculate unadjusted crude ORs, regardless of dose (81 mg/day or 325 mg/day). The NNH was 819 (95% CI 617 to 1119). Subgroup analysis within observational studies: Two observational studies showed a trend for a greater risk of UGIB with increasing (but still low) doses of ASA (23, 46) . Another study showed that the risk of UGIB remained the same (44) . Meta-analysis of the studies examining the risk of UGIB associated with ASA doses ≤100 mg/day found the pooled OR to be 2.6 (95% CI 1.9 to 3.7; P<0.001) ( Figure 5 ). The OR for doses of 300 mg/day to 325 mg/day was 3.6 (95% CI 1.7 to 7.3; P=0.001) ( Figure 5) . A random-effects model was applied because there was a high degree of heterogeneity (I 2 =76% and I 2 =90%, respectively). In the cohort study, the risk was similar for users of ASA 100 mg/day (SIR 2.6 [95% CI 1.8 to 3.5]) and ASA 150 mg/day (SIR 2.6 [95% CI 2.2 to 3.0]); however, it was not clear whether ASA was used in combination with other NSAIDs.
diSCuSSion
The present meta-analysis demonstrates that use of LDA significantly increases the risk of UGIB compared with nonuse. The analysis included data from well-designed RCTs and from observational studies encompassing a broad range and large number of patients (n=87,366). The pooled estimate of the RCTs yielded an OR of 1.5 (95% CI 1.2 to 1.8; P<0.0001) and the observational studies yielded an OR of 3.1 (95% CI 2.5 to 3.7; P<0.0001).
Although RRs are significantly increased, the absolute increases in UGIB risk are small. RCTs involving more than 22,000 patients treated with LDA show that, on average, the number of extra cases of UGIB associated with LDA use are 1.2 per 1000 patients per year. In our analysis, the NNH for the RCTs was 816, meaning that if 816 individuals received LDA rather than placebo for one year, one would have developed UGIB as a result of treatment. The observational studies yielded a very similar NNH of 819.
In spite of different event and/or exposure definitions, several other meta-analyses have examined the risk of gastrointestinal bleeding with LDA use (8) (9) (10) (11) (12) (13) (14) (15) (16) 19, 20) . In general, our findings are consistent with those of others, who reported an absolute rate increase of major gastrointestinal bleeding with LDA use of approximately one per 1000 person-years (11, 14, 19) , with a corresponding NNH of 833 (11) . The RR of gastrointestinal bleeding due to ASA use has been reported to range from 1.5 to 2.5 (8, (10) (11) (12) (13) (14) (15) 19, 20) for clinical trials, and from 2.6 (9) to 3.3 (16) for observational studies. A recently published meta-analysis of RCTs (20) reported a risk of major gastrointestinal bleeding (including lower gastrointestinal bleeding) with LDA use of 1.6 (95% CI 1.3 to 1.9), consistent with the findings from our meta-analysis of the risk of UGIB with LDA use in RCTs. Compared with other previously published reviews and meta-analyses, our analyses included fewer studies. This was due to more stringent inclusion and data extraction criteria; to harmonize the outcome definition across studies, we only included studies in which UGIB could be clearly separated from other gastrointestinal complications such as perforation or lower gastrointestinal bleeding. To harmonize the exposure definition, we included only studies in which LDA dose was clearly reported to be <325 mg/day. Our analysis has extended previous meta-analysis data by specifically examining low dosages of ASA only and focusing on the risk of UGIB rather than gastrointestinal bleeding in general, especially from observational data.
A potential limitation of RCTs is that they often recruit highly selected populations and, therefore, may not be representative of patients seen in routine clinical practice. For example, despite some of the RCTs included in the present analysis, which enrolled patients with a history or a high risk of cardiovascular and cerebrovascular events, all of the RCTs identified excluded certain groups of individuals who would be at an increased risk of bleeding or complications such as those with a history of peptic ulcer disease (6, 21, 22, 42, 43) or individuals who were also treated with NSAIDs, anticoagulants or corticosteroids (21, 22, 32) . The risk of bleeding found in LDA users in these trials may, therefore, be lower than that in the general population. In addition, the majority of RCTs included in the present analysis were post hoc or subgroup analyses of studies in which a cardiovascular or cerebrovascular outcome (and not UGIB) was the original primary outcome measure. Thus, UGIB may have been under-reported, especially after a cardiovascular event occurred. This is supported by the finding that the risk of UGIB associated with LDA use is higher in the observational studies than in the RCTs, although it is possible that residual confounding played a role.
None of the RCTs identified in the present review tested more than one dose level of LDA. However, several of the observational studies examined the dose-response relationship between LDA and UGIB, although the results were inconsistent. For ASA doses ≤325 mg/day, two studies reported an increased trend for UGIB risk with higher doses of ASA (23, 46) . Another study showed the same risk (44) with increased ASA doses.
There is no evidence of a dose-response relationship in terms of the cardiovascular benefit of LDA, and low doses appear to be as effective as high doses (3) . However, all doses of ASA are associated with an increased risk of UGIB. Therefore, there does not appear to be a 'safe' dose of ASA in terms of gastrointestinal risks. This suggests that LDA should be prescribed whenever possible, not only to ensure cardiovascular benefit, but also to reduce the risk of UGIB that is potentially associated with high doses of ASA. This is consistent with European and United States (US) guidelines, which recommend maintenance treatment with ASA 75 mg/day to 100 mg/day for patients with non-ST-segment elevation myocardial infarction (49, 50) . US guidelines on reducing the gastrointestinal risks of antiplatelet therapy recommend that ASA doses >81 mg/day should not be used routinely (51) . Recent studies have highlighted the importance of continuing LDA treatment, even for patients with UGIB (52, 53) . Patients prescribed LDA for secondary prevention of cardiovascular and cerebrovascular events have a 40% increased risk of ischemic stroke or transient ischemic attack for up to six months after discontinuation of ASA treatment compared with patients who continue ASA treatment (54) .
US guidelines recommend concomitant gastroprotection for patients taking LDA who are at risk for upper gastrointestinal events (eg, elderly patients, individuals using other NSAIDs or antithrombotic agents, and patients with a history of peptic ulcer disease) rather than treatment with enteric-coated or buffered LDA (51) . To facilitate a more accurate estimation of the risk of UGIB, the current analysis excluded studies that reported that all participants were treated with proton pump inhibitors (PPIs). However, this guideline recommendation is supported by the finding of Ibáñez et al (24) that the risk of UGIB is lower in patients treated with LDA and a PPI than in those treated with LDA alone (24) . Furthermore, there is evidence from other RCTs that PPI use decreases the incidence of peptic ulcer disease in patients treated with LDA (55, 56) .
The present study, in contrast with previous reviews and metaanalyses, systematically evaluated the association between LDA use and UGIB, both in RCTs and in observational studies. Many previously published meta-analyses have relied on high-quality evidence from RCTs and, although observational studies have some disadvantages, such as the potential for confounding due to the nonrandomized nature of the patient groups, they allow a more representative sample of real-world data to be collected than other study designs.
Despite our efforts to harmonize the outcome definition as much as possible, potential limitations of the included studies include lack of consistency in bleeding definition and ASA dose used, which makes it difficult to compare findings across the studies. In addition, the risk estimates given in the observational studies included in the analysis are influenced by the choice of control group as, for example, in the study by Weil et al (23) A potential limitation of the search strategy was the exclusion of studies published before 1989. However, some of the studies published before 1989 that were included in previous reviews would have been excluded from our study owing to other exclusion criteria, such as not separating UGIB from gastrointestinal bleeding as a whole (57) or not reporting on ASA doses <325 mg/day (58) (59) (60) . In addition, there were many more case-control studies than cohort studies included in our review; only one cohort study was eligible for inclusion in our analysis (30) . To our knowledge, the only other published systematic review of epidemiological studies of upper gastrointestinal complications and ASA use in this time period also included more case-control studies than cohort studies (9) . This may have led to an underestimation of some of the results. However, it does ensure that the focus remains on recent data and that the results are likely to be as representative as possible of current clinical practice.
Another potential limitation is that it was not possible to assess precisely how many individuals in the included studies were being treated with gastroprotective medication. This may have resulted in the incidence of UGIB being underestimated.
All of the observational studies and RCTs included in these analyses show that LDA use is associated with an increased risk of UGIB. Gastroprotective prophylaxis should be considered in patients receiving long-term LDA therapy, particularly in those who have additional risk factors such as concomitant NSAID use or a history of peptic ulcer complications.
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